COVID-19 (Coronavirus)

Reva K. Basho, MD

Assistant Professor, Medicine

Co-Director, Women's Cancer Program

Reva K. Basho, MD

Samuel Oschin Cancer Center
127 S San Vicente Blvd - 7th Floor
Los AngelesCA
90048

Phone:

310-423-8255

Fax:

310-423-4759

Reva K. Basho, MD

Assistant Professor, Medicine

Co-Director, Women's Cancer Program

  • IM/Hematology/Oncology

Reva K Basho, MD specializes in the treatment of breast cancer. Alongside clinical care, she conducts breast cancer research and is the Co-Director of the Women's Cancer Research Program at Cedars-Sinai. Her research focuses on the treatment of high-risk breast cancers and development of novel targeted therapies. Dr. Basho has given multiple lectures to academic audiences on topics pertinent to the treatment of breast cancer. Her research has been funded by multiple sources including the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO). Dr. Basho's work has also been published in high-impact journals including JAMA Oncology, among others. Dr. Basho earned her medical degree from Baylor College of Medicine and completed her residency at the UCLA David Geffen School of Medicine. She completed her hematology and oncology fellowship at MD Anderson Cancer Center. She is board-certified in internal medicine, hematology, and oncology. Dr. Basho is a member of the American Society of Clinical Oncology, American Association for Cancer Research, and the European Society for Medical Oncology.

  • Medical School: Baylor College of Medicine, 2010
  • Residency: UCLA, 2013
  • Fellowship: MD Anderson Cancer Center, 2016
  • Ranked Top 10% Nationally in Patient Experience Performance, 2020
  • The Allison and Brian Grove Endowed Fellowship for Breast Medical Oncology, 2016
  • ASCO/Conquer Cancer Foundation Young Investigator Award, 2016
  • ASCO Merit Award, 2015
  • AACR Scholar-in-Training Award, 2015

Click here for a list of peer-reviewed publications.

  • Basho RK, Gilcrease M, Murthy R, Helgason T, Booser D, Karp D, Meric-Bernstam F, Hess K, Herbrich S, Valero V, Albarracin C, Litton J, Chavez-MacGregor M, Ibrahim N, Murray J, Koenig K, Hong D, Subbiah V, Kurzrock R, Janku F*, Moulder S. Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer (TNBC): evidence of efficacy and proof of concept from a Phase I trial with dose expansion of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab. JAMA Oncol. 2017;3(4):509-515.
  • Basho RK, Yam C*, Gilcrease M, Murthy R, Helgason T, Karp D, Meric-Bernstam F, Hess K, Valero V, Albarracin C, Litton J, Chavez-MacGregor M, Hong D, Kurzrock R, Janku F, Moulder S. Comparative effectiveness of an mTOR-based systemic therapy regimen in advanced, metaplastic and nonmetaplastic triple-negative breast cancer. Oncologist. 2018;23(11):1300-1309.
  • Basho RK, de Melo Gagliato D*, Ueno NT, Wathoo C, Chen H, Wei C, Alvarez R, Moulder S, Sahin A, Roy Chowdhuri S, Chavez-MacGregor M, Litton JK, Valero V, Luthra R, Zeng J, Shaw KR, Mendelsohn J, Mills GB, Tripathy D, Meric-Bernstam F. Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget. 2016;7(47):76362-76373.

English / Hindi

Make an Appointment

Call

1-800-CEDARS-1

(1-800-233-2771)

Available 24 Hours A Day

or

Many of the physicians who have medical staff privileges to practice medicine at Cedars-Sinai Medical Center are independent physicians, and not employees or agents of the hospital. These independent physicians bill separately for their services. You should contact your physician to determine their status and billing practices.